MX2022015835A - Terapias combinadas. - Google Patents

Terapias combinadas.

Info

Publication number
MX2022015835A
MX2022015835A MX2022015835A MX2022015835A MX2022015835A MX 2022015835 A MX2022015835 A MX 2022015835A MX 2022015835 A MX2022015835 A MX 2022015835A MX 2022015835 A MX2022015835 A MX 2022015835A MX 2022015835 A MX2022015835 A MX 2022015835A
Authority
MX
Mexico
Prior art keywords
combination therapies
inhibitor
bcl
kits
compositions
Prior art date
Application number
MX2022015835A
Other languages
English (en)
Inventor
Daniel P Gold
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of MX2022015835A publication Critical patent/MX2022015835A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)

Abstract

En el presente documento se proporcionan composiciones, métodos y kits para tratar el cáncer que comprenden un inhibidor mitocondrial y un inhibidor de Bcl-2.
MX2022015835A 2020-06-11 2021-06-10 Terapias combinadas. MX2022015835A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063037750P 2020-06-11 2020-06-11
PCT/US2021/036833 WO2021252776A1 (en) 2020-06-11 2021-06-10 Combination therapies

Publications (1)

Publication Number Publication Date
MX2022015835A true MX2022015835A (es) 2023-01-24

Family

ID=78845904

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015835A MX2022015835A (es) 2020-06-11 2021-06-10 Terapias combinadas.

Country Status (8)

Country Link
US (1) US20230233519A1 (es)
EP (1) EP4164632A4 (es)
JP (1) JP2023530253A (es)
CN (1) CN116113414A (es)
AU (1) AU2021286662A1 (es)
CA (1) CA3181730A1 (es)
MX (1) MX2022015835A (es)
WO (1) WO2021252776A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215785A1 (en) * 2022-05-05 2023-11-09 The Johns Hopkins University Platelet-activating factor blockade inhibits tumor growth

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2953938T (pt) * 2014-02-07 2017-10-09 Novogen ltd Compostos de benzopirano funcionais e sua utilização
PT3253208T (pt) * 2015-02-02 2021-06-17 The Spanish National Cancer Res Centre Terapêuticas de combinação para utilização no tratamento do cancro da mama

Also Published As

Publication number Publication date
JP2023530253A (ja) 2023-07-14
WO2021252776A1 (en) 2021-12-16
AU2021286662A1 (en) 2023-02-09
US20230233519A1 (en) 2023-07-27
EP4164632A1 (en) 2023-04-19
EP4164632A4 (en) 2024-06-05
CN116113414A (zh) 2023-05-12
CA3181730A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2022004370A (es) Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda.
EP4268898A3 (en) Kras g12c inhibitors for treating cancer
MX2020012139A (es) Composiciones y metodos para tratar rosacea y acne.
WO2018195439A3 (en) K-ras modulators
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
AU2019310335A8 (en) Methods of treating cancer with PI3K inhibitor, GDC-0077
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
MX2022010977A (es) Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos.
MX2022010975A (es) Inhibidores de egfr, kras, braf y otras dianas y uso de estos.
MX2022008099A (es) Tratamiento para el cancer con inhibidores de cdk12/13.
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
BR112022008295A2 (pt) Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
MX2022015835A (es) Terapias combinadas.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2022014180A (es) Metodos, terapias y usos para tratar cancer.
AR113805A1 (es) Composiciones y métodos para tratar cáncer hepático
WO2022261183A3 (en) Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
MX2023005171A (es) Composiciones y metodos para tratamiento de cancer solido.
CO2022009433A2 (es) Uso de isatuximab para el tratamiento del mieloma múltiple recidivante y/o refractario
MX2021013908A (es) Tratamiento para el cáncer.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
MX2023005530A (es) Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon.